Greenwich Total Stockholder Equity from 2010 to 2024

GLSI Stock  USD 14.25  0.32  2.20%   
Greenwich Lifesciences' Total Stockholder Equity is increasing with slightly volatile movements from year to year. Total Stockholder Equity is estimated to finish at about 11.5 M this year. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2010-12-31
Previous Quarter
6.7 M
Current Value
11.5 M
Quarterly Volatility
14 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Greenwich Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Greenwich Lifesciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4 K, Interest Expense of 259.6 K or Selling General Administrative of 1.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 21.18. Greenwich financial statements analysis is a perfect complement when working with Greenwich Lifesciences Valuation or Volatility modules.
  
Check out the analysis of Greenwich Lifesciences Correlation against competitors.
For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.

Latest Greenwich Lifesciences' Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of Greenwich Lifesciences over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Greenwich Lifesciences' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Greenwich Lifesciences' overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Slightly volatile
   Total Stockholder Equity   
       Timeline  

Greenwich Total Stockholder Equity Regression Statistics

Arithmetic Mean(434,708)
Geometric Mean10,086,705
Coefficient Of Variation(3,228)
Mean Deviation11,744,510
Median(10,120,054)
Standard Deviation14,032,270
Sample Variance196.9T
Range37.8M
R-Value0.74
Mean Square Error96.8T
R-Squared0.54
Significance0
Slope2,313,444
Total Sum of Squares2756.7T

Greenwich Total Stockholder Equity History

202411.5 M
20236.7 M
202213.2 M
202126.8 M
202027.6 M
2019-1.4 M

About Greenwich Lifesciences Financial Statements

Investors use fundamental indicators, such as Greenwich Lifesciences' Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Greenwich Lifesciences' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Total Stockholder Equity6.7 M11.5 M

Currently Active Assets on Macroaxis

When determining whether Greenwich Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Greenwich Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Greenwich Lifesciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Greenwich Lifesciences Stock:
Check out the analysis of Greenwich Lifesciences Correlation against competitors.
For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.81)
Return On Assets
(0.72)
Return On Equity
(1.24)
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.